Active specific immunotherapy in ovarian cancer. 1978

M E Crowther, and L Levin, and T A Poulton, and M J Saffrey, and O M Curling, and C N Hudson

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M E Crowther, and L Levin, and T A Poulton, and M J Saffrey, and O M Curling, and C N Hudson
January 2010, The Cochrane database of systematic reviews,
M E Crowther, and L Levin, and T A Poulton, and M J Saffrey, and O M Curling, and C N Hudson
September 2014, The Cochrane database of systematic reviews,
M E Crowther, and L Levin, and T A Poulton, and M J Saffrey, and O M Curling, and C N Hudson
September 2018, The Cochrane database of systematic reviews,
M E Crowther, and L Levin, and T A Poulton, and M J Saffrey, and O M Curling, and C N Hudson
January 1982, Anales de la Real Academia Nacional de Medicina,
M E Crowther, and L Levin, and T A Poulton, and M J Saffrey, and O M Curling, and C N Hudson
January 2005, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
M E Crowther, and L Levin, and T A Poulton, and M J Saffrey, and O M Curling, and C N Hudson
October 2003, Expert review of anticancer therapy,
M E Crowther, and L Levin, and T A Poulton, and M J Saffrey, and O M Curling, and C N Hudson
January 2000, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],
M E Crowther, and L Levin, and T A Poulton, and M J Saffrey, and O M Curling, and C N Hudson
October 2016, Immunotherapy,
M E Crowther, and L Levin, and T A Poulton, and M J Saffrey, and O M Curling, and C N Hudson
January 2000, Seminars in surgical oncology,
M E Crowther, and L Levin, and T A Poulton, and M J Saffrey, and O M Curling, and C N Hudson
October 1981, British journal of cancer,
Copied contents to your clipboard!